Business Wire

Adva Network Security Layer 2 encryption technology achieves German BSI approval

2.2.2023 11:00:00 EET | Business Wire | Press release

Share

Adva Network Security today announced that its flagship 10Gbit/s edge solution with ConnectGuard Ethernet encryption has been approved for the transmission of classified data by the German Federal Office for Information Security (BSI). With BSI clearance to transport VS-NfD and NATO RESTRICTED (NR) information, the FSP 150-XG118Pro (CSH) enables customers to deploy a secure network access device guaranteed to meet stringent regulatory requirements. With comprehensive demarcation capabilities and an optional server blade, the device offers several additional advantages, such as precise synchronization and NFV hosting. Its approval by the BSI will be a major boost for customers with high security standards.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230201005865/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

BSI approval for Adva Network Security’s 10G Ethernet device will prove key for data protection at the network edge. (Photo: Business Wire)

“We work with public authorities, critical infrastructure operators and enterprises whose networks are particularly threatened by cyberattacks as they often contain the most sensitive and mission-critical data. Today’s announcement will be big news for them. Now it’s possible to securely harness a 10Gbit/s edge solution with a unique set of capabilities such as next-generation timing delivery, network virtualization and comprehensive service assurance,” said Michael Roth, GM of Adva Network Security. “We were the first in the industry to attain BSI clearance for our Layer 1 technology. Now it’s the turn of our Layer 2 solution. As a qualification, BSI approval is one of the most challenging in the industry. Achieving it not only highlights the power of the protection offered by our device, but also our commitment to security in all our business processes.”

The FSP 150-XG118Pro (CSH) is a compact, power-efficient solution for network access that combines 10Gbit/s Carrier Ethernet, IP service demarcation, and aggregation with a rich set of programmability and synchronization features. It offers robust network protection with dynamic key exchange and hardware tamper protection for the most sensitive data, and is also ready to support quantum-safe key exchange. The approval of the FSP 150-XG118Pro (CSH) by the BSI follows certification for the ADVA FSP 3000 Layer 1 encryption solution, which is already playing a key role in the transport of EU- and NATO-classified data. Customers can now have complete peace of mind that their data at both Layers 1 and 2 is secured to the most rigorous standards and compliance requirements.

“Public authorities and critical infrastructure use wide area networks and are looking to apply end-to-end encryption to standard MEF services that meet the strictest industry standards. Now our FSP 150-XG118Pro (CSH) offers a solution that ensures BSI-approved security for metro networks along with the key capabilities needed to deliver tomorrow’s services,” commented Uli Schlegel, senior director of product line management at Adva Network Security. “Our FSP 150-XG118Pro (CSH) meets tight constraints for latency, power and size. It includes a rich set of operational features and supports a pluggable server module for hosting virtualized network functions. With BSI approval, it’s the ultimate choice for rapid innovation and security at the network edge.”

Further information on the FSP 150-XG118Pro (CSH) is available in this video: https://youtu.be/6w7Z3CLBRFE.

About Adva Network Security
Adva Network Security has built a fierce reputation for protecting packet optical networks. We pioneered low-latency, multi-layer encryption solutions that are right now safeguarding data in motion for many mission-critical applications. Our ConnectGuardTM security technology is even combating tomorrow’s quantum security threats. Built by the industry’s leading security experts, our German-based organization helps organizations and government agencies security-harden their networks to ensure critical infrastructure is protected against cyber threats. Our development and manufacturing processes, as well as our security solutions, have been approved and certified by leading governmental security agencies. For more information on how we can help you, please visit www.advasecurity.com.

Published by
Adva Network Security GmbH, Berlin, Germany
www.advasecurity.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For media
Gareth Spence
t +44 1904 699 358
public-relations@adva.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted

Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release

Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory

Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release

Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off

Speech Processing Solutions Launches Philips SpeechLive Legal AI Assistant for Faster, More Accurate Legal Document Creation5.8.2026 16:37:00 EEST | Press release

Speech Processing Solutions, the global leader in AI-assisted professional dictation and documentation solutions sold under the Philips brand, today announced the Philips SpeechLive Legal AI Assistant. The new solution transforms voice recordings, dictation and uploaded sources into structured, ready-to-review legal documents, helping legal professionals work faster while retaining control of the final draft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805997413/en/ The new Philips SpeechLive Legal AI Assistant is designed for turning conversations into ready-to-review legal document drafts. SpeechLive Legal significantly reduces the time needed to transform voice input into structured legal documentation, delivering consistent and high-quality drafts and featuring SpeechLive's built-in integrations with leading case management platforms such as Actionstep, Clio, iManage and NetDocuments, supporting existing billing, e

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye